Nektar Therapeutics NKTR EBITDA

EBITDA at other companies

AmgenAMGN

$4.63B+15.7%

Regeneron PharmaceuticalsREGN

$1.42B+16.7%

ImmunityBio, Inc.IBRX

-$65.41M-7.9%

Apogee Therapeutics, Inc.APGE

-$82.36M-31.0%

Artiva Biotherapeutics, Inc.ARTV

-$26.2M-18.2%

Vera TherapeuticsVERA

-$124.99M-119%

FAQ

What is Nektar Therapeutics's EBITDA?

Nektar Therapeutics (NKTR) reported EBITDA of -$38.9M in Q1 2026.

How has Nektar Therapeutics's EBITDA changed year-over-year?

Nektar Therapeutics's EBITDA increased by 11.8% year-over-year, from -$44.11M to -$38.9M.

What is the long-term trend for Nektar Therapeutics's EBITDA?

Over 4 years (2021 to 2025), Nektar Therapeutics's EBITDA has grown at a -24.7% compound annual growth rate (CAGR), from -$431.96M to -$139.08M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.